|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2010-4-29
|
|
pubmed:abstractText |
A weekly administration of alternating irinotecan or oxaliplatin associated to 5-Fluorouracil in advanced colorectal cancer was planned in order to evaluate a new schedule maintaining dose intensities of each drug as in double combinations and tolerability of the triplet association. The following weekly schedule was administered: irinotecan, days 1 and 15; oxaliplatin, days 8 and 22; 5-fluorouracil (5-FU) over 12-h (from 10:00 p.m. to 10:00 a.m.) timed flat infusion, days 1-2, 8-9, 15-16 and 22-23, every 4 weeks. Dose- finding and phase II study were planned. Thirteen patients were enrolled in the dose-finding study and 23 in the phase II study. The recommended doses of our study are: irinotecan 160 mg/m(2); oxaliplatin 80 mg/m(2); 5-FU 900 mg/m(2). The dose-limiting toxicity was diarrhea (35% of patients) but no cases of febrile neutropenia were observed. In 30 patients assessable for response two complete (6.7%) and 18 partial (60%) responses were observed, for an overall response rate of 66.7% (alpha 0.05, CI+/-17). The triplet association using this weekly alternating schedule is an active and well-tolerated outpatient regimen. Surgical removal of residual disease was considered in 5 patients and a radical resection was performed in 5 patients (147 %).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1791-2431
|
|
pubmed:author |
pubmed-author:BrueraGG,
pubmed-author:CalistaFF,
pubmed-author:CannitaKK,
pubmed-author:De GalitiisFF,
pubmed-author:FicorellaCC,
pubmed-author:GebbiaNN,
pubmed-author:GuglielmiFF,
pubmed-author:IacobelliSS,
pubmed-author:Lanfiuti BaldiPP,
pubmed-author:ManciniMM,
pubmed-author:MarchettiPP,
pubmed-author:MartelliNN,
pubmed-author:MorelliM FMF,
pubmed-author:PelliccioneMM,
pubmed-author:PorzioGG,
pubmed-author:RicevutoEE,
pubmed-author:RussoAA,
pubmed-author:SantomaggioAA,
pubmed-author:TudiniMM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1635-40
|
|
pubmed:meshHeading |
pubmed-meshheading:20428819-Adult,
pubmed-meshheading:20428819-Aged,
pubmed-meshheading:20428819-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20428819-Camptothecin,
pubmed-meshheading:20428819-Colorectal Neoplasms,
pubmed-meshheading:20428819-Dose-Response Relationship, Drug,
pubmed-meshheading:20428819-Female,
pubmed-meshheading:20428819-Fluorouracil,
pubmed-meshheading:20428819-Humans,
pubmed-meshheading:20428819-Liver Neoplasms,
pubmed-meshheading:20428819-Lung Neoplasms,
pubmed-meshheading:20428819-Lymphatic Metastasis,
pubmed-meshheading:20428819-Male,
pubmed-meshheading:20428819-Maximum Tolerated Dose,
pubmed-meshheading:20428819-Middle Aged,
pubmed-meshheading:20428819-Organoplatinum Compounds,
pubmed-meshheading:20428819-Survival Rate,
pubmed-meshheading:20428819-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study.
|
|
pubmed:affiliation |
IDI-Istituto Dermopatico dell'Immacolata, Rome, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|
